Company Description: The mission of Everfront Biotech is to address unmet medical needs by developing orphan drugs to treat some of the world's deadliest diseases, including high-grade gliomas and pancreatic cancer. Guided by innovative drug development directions, we employ small molecule targeted drugs as effective treatment components, emphasizing local-sustained drug delivery strategies to enhance therapeutic efficacy. We also bolster the body's immune system to combat cancer and release drugs with synergistic effects to strengthen treatment outcomes. Our products shape the future of tumor treatment, such as the Cerebraca® Wafer (local-sustained treatment), which has the potential to become the best choice for surgical combination therapy, exhibiting a significant median survival period of 26.2 months in recurrent high-grade glioma patients, surpassing the current therapy of 6-9 months, and targeting a global market worth $4 billion annually. We are currently initiating Phase IIb global clinical trials for accelerated approval and Phase I/IIa pancreatic cancer clinical trials for indication expansion. We are also committed to advancing diversified clinical fields, including EFs soft capsules (systemic therapy), for the treatment of cancer, neurodegenerative diseases, and fibrotic diseases, targeting a global market worth $73 billion annually and conducting Phase I clinical trials in healthy subjects for drug safety profile. Built on a solid foundation and collaboration, we are focusing on patent-driven, product development, innovative research, and experienced management, dedicated to advancing new drug development.